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A b s t r a c t
Antiplatelet therapy with P2Y
12 
receptor inhibitors has become the cornerstone of medical treatment in patients with acute coro-
nary syndrome, after percutaneous coronary intervention and in secondary prevention of atherothrombotic events. Clopidogrel used 
to be the most broadly prescribed P2Y
12 
receptor inhibitor with undisputable benefits especially in combination with aspirin, but 
a considerable number of clopidogrel-treated patients experience adverse thrombotic events in whom insufficient P2Y
12
-inhibition 
and a consequential high on-treatment platelet reactivity is a common finding. This clinically relevant limitation of clopidogrel has 
driven the increased use of new antiplatelet agents. Prasugrel (a third generation thienopyridine) and ticagrelor (a cyclopentyl-tri-
azolo-pyrimidine) feature more potent and predictable P2Y
12
-inhibition compared to clopidogrel, which translates into improved 
ischemic outcomes. However, excessive platelet inhibition and consequential low on-treatment platelet reactivity comes at the 
price of increased risk of major bleeding. The majority of randomized clinical trials failed to demonstrate improved clinical outcomes 
with platelet function testing and tailored antiplatelet therapy, but results of all recent trials of potent antiplatelets and prolonged 
antiplatelet durations point towards a need for individualized antiplatelet approach in order to decrease thrombotic events without 
increasing bleeding. This review focuses on potential strategies for personalizing antiplatelet treatment. 
Key words: antiplatelet therapy, P2Y
12
 receptor inhibitors, acute coronary syndromes, platelet reactivity.
Review paper
Corresponding author: 
Jolanta Siller-Matula MD, PhD, Department of Cardiology, Medical University of Vienna, 1090 Vienna, Austria, phone: +43 1 40400 46140,  
fax: +43 1 40400 42160, e-mail: jolanta.siller-matula@meduniwien.ac.at 
Received: 5.11.2015, accepted: 5.11.2015.
Atherothrombosis
Atherosclerotic plaque rupture or erosion is thought 
to be the initial step in the development of acute coro-
nary syndrome (ACS). At the site of vascular injury (due 
to plaque rupture) exposed subendothelial matrix recruits 
and activates platelets [1]. Platelets adhere to exposed 
collagen and von Willebrand factor (vWF). Via the platelet 
glycoprotein (GP)-VI receptor and integrin α2β1, collagen 
can directly bind to and activate platelets, which leads to 
release of contents from the dense granules to the ex-
tracellular surrounding. Dense granules mostly consist of 
platelet agonists such as adenosine diphosphate (ADP), 
epinephrine, serotonin, thrombin, thromboxane A
2
, which 
in turn promote aggregation, recruitment, and further 
activation of circulating platelets. The α-granules contain 
fibrinogen, factor V and P-selectin. ADP binds to platelet 
P2Y12 and P2Y1 receptors and by that amplifies the effect 
of other agonists such as thrombin [1–3]. Activation induc-
es changes in platelet shape, increase of surface by pseu-
dopodia and secretion of further storage products. In the 
final step, GP IIb/IIIa is converted into its active form, which 
binds fibrinogen and vWF, leading to stable platelet aggre-
gates and subsequent thrombus formation [4]. Additional-
ly, the vascular injury exposes tissue factor which initiates 
the extrinsic clotting cascade and leads to generation of 
more thrombin and the propagation of the fibrin clot [5]. 
P2Y12 receptor
The P2Y
12
 receptor is a member of the P2Y purinergic 
G protein-coupled receptors (GPCR) family, which is ac-
tivated by ADP, thromboxane A
2
 and the PAR-1 receptor 
agonists [6, 7]. Activation of the P2Y
1
 receptor by ADP in-
itiates a weak and transient phase of platelet aggrega-
tion whereas binding of ADP to the P2Y
12
 amplifies dense 
granule secretion, expression of P-selectin and platelet 
aggregation [8]. Further stimulation of the P2Y
12
 recep-
tor
 
sustains the activation of the GP IIb/IIIa and GP Ia/IIa 
receptors and stabilization of platelet aggregates [9, 10].
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P2Y12 receptor antagonism
Combination of aspirin with P2Y
12
 receptor antag-
onists has been proven in a multitude of trials to have 
a favourable synergistic effect in patients after coronary 
stent implantation [11]. To date, ticlopidine, clopidogrel, 
prasugrel, ticagrelor and an intravenous compound, can-
grelor, have been approved by the Food and Drug Admin-
istration (FDA) [1, 12, 13].
Ticlopidine
Ticlopidine, a first-generation thienopyridine, was the 
first FDA-approved P2Y
12 
receptor inhibitor in clinical use 
[14]. It was the first drug that showed a decrease in major 
cardiovascular events in patients after stroke compared 
to aspirin or placebo, and in patients after percutaneous 
coronary intervention (PCI) compared to warfarin-based 
regimens [15]. Nevertheless, severe side effects like aplas-
tic anaemia and agranulocytosis and slow onset of action 
limit the use of the compound and have led to the devel-
opment of clopidogrel [16]. 
Clopidogrel
Clopidogrel, a  second-generation thienopyridine-type 
irreversible inhibitor of the P2Y
12
 receptor, has a more fa-
vourable safety profile compared to the ticlopidine. It is 
a pro-drug, requiring enteric and hepatic transformation 
by the cytochrome P450 (CYP) system to exert its anti-
platelet effect. After absorption, up to 85% of clopidogrel is 
hydrolyzed by carboxyesterase-1 to an inactive metabolite, 
SR26334. The remaining approx. 15% of clopidogrel are 
metabolized to the active compound, R-130964, in a two-
step process via formation of 2-oxo-clopidogrel. CYP 2C19 
seems to have the most prominent role in this process, 
with less involvement of CYP2B6, CYP1A2, CYP3A/A5, and 
CYP2C9 [17, 18] (Figure 1). After administration of a 600 mg 
clopidogrel loading dose, the maximum achievable inhi-
bition of ADP-induced platelet aggregation of 40–60% is 
achieved within 2 to 6 h [19].
Next generation P2Y12 inhibitors
Despite the proven benefits of aspirin and clopi-
dogrel, a non-negligible proportion of patients continue 
to experience recurrent ischemic events. These clinical 
failures have been attributed to response variability 
and to a relatively slow onset of action with clopidogrel 
and have prompted the development of new oral P2Y
12
 
inhibitors. Additionally, it has been shown that a mod-
erate platelet inhibition by clopidogrel is insufficient to 
suppress an increase in ADP-induced platelet aggrega-
tion in the midmorning, in the period when myocardial 
infarction (MI), stroke and sudden cardiac death occur 
the most frequently [20–23]. Both prasugrel and ticagr-
elor have shown to have a  more consistent, rapid and 
potent P2Y
12 
receptor inhibition than clopidogrel, which 
translated into reduction in the ischemic events at the 
costs of bleeding events [12, 24–29]. 
Prasugrel
Prasugrel is a third generation thienopyridine, which 
acts as an irreversible inhibitor of the P2Y
12
 receptor. Like 
clopidogrel, prasugrel is a pro-drug and requires hepatic 
bioactivation. The active metabolite is formed in a  sin-
gle-step oxidation via various CYP isoenzymes (CYP3A4/5, 
CYP2B6, CYP2C19, CYP2C9) [30] (Figure 1). 
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Figure 1. Metabolism of P2Y
12
 receptor inhibitors
ADP – adenosine diphosphate, CYP – cytochrome 450. 
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It’s worth noting that the known functional genetic 
CYP variants do not significantly affect formation of the 
active metabolite of prasugrel, that is faster and more 
efficient resulting in greater in vivo antiplatelet potency 
compared to clopidogrel [31, 32].
Ticagrelor
Ticagrelor, a cyclopentyl-triazolo-pyrimidine, is an oral 
antagonist of the P2Y
12
 receptor, and unlike clopidogrel 
and prasugrel it is an active, noncompetitive antagonist 
of the P2Y
12
 receptor. As an active drug ticagrelor does 
not require hepatic bioactivation, but has a  metabolite 
(AR-C124910XX) formed by metabolism via CYP3A4, with 
also anti-aggregatory effects [33] (Figure 1). Genetic fac-
tors including CYP2C19 and ABCB1 polymorphisms do 
not influence the clinical outcome of ticagrelor-treated 
patients [34]. Ticagrelor is active immediately after oral 
administration, which results in a  more rapid onset of 
action and a more pronounced platelet inhibition com-
pared to clopidogrel [35]. 
The unprecedented mortality benefits observed in 
the PLATO trial, despite only a  moderate decrease in 
the occurrence of MI, led to a hypothesis that ticagrelor 
therapy was associated with off-target effects [36]. Since 
P2Y
12
 receptors were identified on vascular smooth mus-
cle cells (VSMCs), we and others have earlier demonstrat-
ed in animal and human models that ticagrelor, but not 
clopidogrel and prasugrel, prevents ADP-induced VSMC 
contraction [37]. Additionally, other groups have demon-
strated that ticagrelor inhibited the uptake of adenosine 
by human erythrocytes [38] and also induced the release 
of adenosine triphosphate from human erythrocytes, 
that is, followed by its degradation to adenosine [39]. 
The former mechanism was proposed to explain the en-
hancement of adenosine-induced increase in coronary 
blood flow observed in a canine model by ticagrelor [38]. 
High on-treatment platelet reactivity 
In clinical practice, antiplatelet drugs are adminis-
tered to patients at standard doses, without monitoring 
their pharmacological response as it is done in case of 
warfarin therapy guided by INR-control [40]. This fixed-
dose or better “one size fits all” approach with clopi-
dogrel therapy is a remnant of clinical trials and does not 
take the inter-individual pharmacodynamic variability 
of ADP-pathway inhibitors into account [41]. Starting in 
2003, studies suggested that the level of platelet inhi-
bition, especially by clopidogrel, considerably varies be-
tween patients [41, 42].
Dependent on the assay used and the population 
studied, up to 25–50% of clopidogrel-treated patients 
fail to show adequate pharmacological response to clopi-
dogrel and are not adequately protected from major 
adverse cardiac events (MACE) [43–45]. There is robust 
data showing an association between clopidogrel non-re-
sponsiveness or high on-treatment platelet reactivity 
(HPR) and adverse ischemic events, with the strongest 
association for short-term thrombotic events, like acute 
and subacute stent thrombosis, in patients after PCI [42, 
46–55]. Nevertheless, the routine measurement of plate-
let reactivity has not been widely implemented and rec-
ommended in the guidelines. At least 40 studies demon-
strated that ADP-induced platelet function testing is the 
best predictor of ischemic events in clopidogrel non-re-
sponders [54, 56–58]. Likewise, measurement of plate-
let function by light transmission aggregometry (LTA) in 
patients undergoing coronary stenting might predict ad-
verse events [59–62]. Other tests, including the new gen-
eration impedance aggregometry test (Multiplate, MEA), 
VerifyNowTM and the vasodilator stimulated phosphopro-
tein (VASP) phosphorylation assay, have confirmed the 
association between poor clopidogrel responsiveness 
and increased risk of cardiac ischemic events during 
short- and long- term follow-up [46, 48, 63–69]. Never-
theless, lack of consensus concerning optimal method 
to quantify HPR and the best cut-off value associated 
with clinical risk has hindered the consideration of plate-
let function testing (PFT) in clinical guidelines. However, 
a recent analysis involving more than 20,000 patients af-
ter PCI tested uniformly-defined cutoff values for three 
relatively well-standardized assays (MEA, VerifyNow and 
VASP) and identified sharp cut points for HPR that were 
highly significant predictors of stent thrombosis and 
cardiovascular mortality [70]. 
Although new platelet aggregation inhibitors were 
invented to overcome HPR, it has been shown that this 
phenomenon is not exclusively true for clopidogrel treat-
ment. In the acute phase of ST-elevation myocardial in-
farction (STEMI) 37% of the patients treated with pra-
sugrel and 46% treated with ticagrelor exhibited HPR [69, 
71–76]. Interestingly, a  recent study has indicated that 
12% of prasugrel-treated patients presented with the 
HPR phenotype [77], which might be explained by the 
fact that 43% of included patients displayed HPR under 
clopidogrel treatment and were switched to prasugrel 
[77]. Similarly, the TAILOR study as well as randomized 
trials in haemodialysis patients have shown that up to 
20% of patients continued to exhibit HPR despite switch 
from clopidogrel to prasugrel [73, 74, 78]. Noteworthy, 
in the MADONNA study, direct switch to prasugrel from 
clopidogrel was associated with a  satisfactory level of 
platelet inhibition by prasugrel in all patients [79]. Not 
surprisingly, however, the platelet inhibitory effect in pa-
tients treated with therapeutic hypothermia after cardiac 
arrest was reduced in prasugrel and ticagrelor treated pa-
tients reaching an incidence of HPR of 32% and 30%, re-
spectively [80]. Interestingly, some studies indicated that 
in ACS patients with HPR while on clopidogrel ticagrelor 
produced stronger platelet inhibition compared with pra-
sugrel [81]. Noteworthy, switching from ticagrelor main-
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tenance dose to prasugrel maintenance dose was associ-
ated with a lower level of platelet inhibition as compared 
to continued ticagrelor therapy [82]. Nevertheless, at day 
7 there was no difference in HPR frequency between the 
prasugrel and ticagrelor groups [82]. In ACS patients one 
month after the event ticagrelor was more effective than 
prasugrel in a pharmacodynamic study [83]. Interestingly, 
the antiplatelet activity of ticagrelor’s active metabolite 
was more potent compared to ticagrelor or prasugrel’s 
active metabolite in both humans and nonhuman pri-
mates [84]. 
Therefore, although the rate of HPR is lower with 
novel P2Y
12
-inhibitors, it is not an exclusive feature of 
clopidogrel. While clinical, genetic and demographic vari-
ables associated with HPR in clopidogrel-treated subjects 
are well defined and the worse clinical course in such 
patients is unquestionable, such factors and clinical im-
pacts should be investigated and clarified in future trials 
in case of prasugrel and ticagrelor. 
Clinical factors associated with HPR 
Drug-drug interactions, obesity, renal dysfunction, di-
abetes mellitus (DM), higher age, reduced left ventricular 
function, inflammation and the presence of an ACS are 
all associated with inadequate response to clopidogrel 
therapy and consequential HPR [85–90]. For further risk 
stratification, it has been suggested to use scoring sys-
tems that can integrate clinical risk factors and genetic 
variants identified by path models [91, 92]. 
Drug-drug interactions
It has been shown that certain proton pump inhibi-
tors such as omeprazole, calcium channel blockers, ke-
toconazole and rifampicin may significantly influence 
clopidogrel metabolism [87, 93–102]. Interestingly, mor-
phine co-medication in ACS is a strong predictor of HPR 
in patients treated with clopidogrel, prasugrel and tica-
grelor. This effect might be partially explainable by the 
impaired or delayed absorption of those drugs induced 
by opioid-induced gastroparesis [76, 103, 104]. 
Diabetes mellitus
Among all clinical risk factors accounting for HPR, 
DM has a unique position. DM is a strong independent 
predictor of short-term and long-term recurrent ischem-
ic events and mortality in the ACS setting [105]. The 
reported negative impact on mortality includes all ACS 
subtypes and especially the increased risk for short-term 
ischemic events suggests an important role of platelet 
activation-aggregation. 
It is well evidenced that platelets of DM patients ex-
hibit an increased reactivity, caused by dysregulation of 
several signalling pathways by hyperglycaemia, insulin 
resistance, metabolic conditions and inflammation [106]. 
Direct insulin effect on platelets
In general, insulin exhibits anti-aggregatory effects 
and this antithrombotic effects are diminished in diabet-
ic patients [107]. Insulin can exhibit direct anti-aggrega-
tory effect via attenuation of the thrombin-induced Ca2+ 
response and the release of ADP as well as inhibition of 
the P2Y
12
 receptor [108, 109]. Furthermore, it enhances 
the platelet inhibitory effects of prostaglandin (PG) E1 
and I2 (Figure 2) [110]. 
Hyperglycaemia 
Hyperglycaemia has been shown to increase platelet 
reactivity in various ways (Figure 3). It induces P-selectin 
expression, alters membrane fluidity with subsequent 
platelet adhesion and activates protein C [106, 111]. 
In DM patients with ACS, glucose lowering therapy is 
proven beneficial independent of the treatment strategy 
[112, 113]. 
Insulin deficiency and resistance
Both insulin receptors and the insulin-like growth 
factor-1 (IGF-1) are expressed on thrombocytes. Binding 
of insulin to the platelets’ insulin receptor increases sur-
face expression of adenylate cyclise-linked prostacyclin 
receptor, but due to the low Insulin receptor expression, 
the effect is negligible. IGF-1 is stored in the α-granules 
of platelets, which may contribute to the amplification 
of platelet aggregation after alpha granule release [114]. 
Other mechanisms how insulin resistance affect platelet 
aggregation include increased intracellular calcium with 
chanced platelet degranulation, impaired response to 
prostacyclin and nitric oxide [115, 116].
PGE1
INSULIN
PGI1
NO
PAI-1
PGE1
PGI2
PGI1
PGE2
ADP
Collagen
Epinephrine
Thrombin
IRS-1
Figure 2. Effects of insulin on blood cells
PGE1 – prostaglandin E1, PGI2 – prostaglandin I2, NO – nitric oxide,  
ADP – adenosine diphosphate, PAI-1 – plasminogen activator inhibitor 1.
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Metabolic conditions
The DM is often accompanied by obesity, dyslipidem-
ia, and enhanced systemic inflammation, every single 
one of which may contribute to the increased platelet 
reactivity. Obesity may enhance platelet aggregation via 
similar pathomechanisms as insulin resistance: higher 
mean platelet volume, high blood leptin, increased intra-
cellular calcium concentration [106]. 
HPR in diabetic patients 
A multitude of trials have proven the benefit of clopi-
dogrel in combination with aspirin in post-ACS DM pa-
tients. Nevertheless, HPR under clopidogrel therapy is 
more prevalent in diabetic compared with non-diabetic 
patients, especially in those requiring insulin therapy 
[105, 107]. Similar factors leading to increased platelet re-
activity in DM patients also cause HPR to clopidogrel. To 
date, only small in vitro and ex vivo studies have identified 
the following factors to cause HPR: lack of response to 
insulin in platelets, changes in calcium metabolism, P2Y
12
 
receptor signalling upregulation, increased exposure to 
ADP, and increased platelet turnover [106, 117, 118].
Another interesting mechanism for impaired P2Y
12
 in-
hibition mediated by clopidogrel among DM patients has 
been linked to attenuation of clopidogrel‘s pharmacoki-
netics, which was characterized by lower plasma levels of 
clopidogrel active metabolite as compared with non-dia-
betic patients [119].
Low on-treatment platelet reactivity 
and the therapeutic window concept
Some studies postulated that there might be a ther-
apeutic window for P2Y
12
 receptor blockers, indicating 
that while HPR is associated with thrombotic events, 
low on-treatment platelet reactivity (LPR) may be related 
to bleeding events [61, 64, 65, 120–122]. The two sides 
of the coin regarding P2Y
12
-inhibition, i.e. higher risk for 
thrombosis in HPR and higher risk for bleeding in LPR 
suggest that a sweet spot may exist for P2Y
12
-inhibition. 
Validation of such therapeutic window with patients 
having optimal platelet reactivity was recently reported 
in a  collaborative analysis including more than 20,000 
patients [70]. According to the results, patients with LPR 
had an absolute 1.2% lower risk for stent thrombosis and 
Figure 3. Effects of hyperglycaemia on platelets
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2.7% lower risk for bleeding, compared to HPR and LPR, 
respectively [70]. 
Test systems used for assessment of the 
effect of antiplatelet drugs 
The effect of clopidogrel on platelet function can be 
measured by platelet function testing and corresponds 
to the phenotype of its response. There are several test 
systems available for monitoring the effect of antiplate-
let drugs, all characterizing different pathways of plate-
let activation, unfortunately with no option to reflect the 
complexity of platelet biology. 
Platelet aggregometry
Platelet aggregometry is based on the stimulation of 
platelet aggregation with different agents. There are two 
commercially available techniques: optical and imped-
ance aggregometry. 
Light transmission aggregometry
Light transmission aggregometry (LTA) used to be the 
most widespread platelet function test. P2Y
12
 receptor in-
hibition is measured by adding ADP and the change in 
the light transmittance is recorded. The maximal aggre-
gation and the final aggregation responses can be meas-
ured and expressed as percentage (Table I). The wide-
spread use and the reported good correlation between 
the measured aggregation responses and adverse events 
are the most important advantages of optical aggregom-
etry. Time-consuming centrifugation steps as well as the 
large sample volume needed and variable reproducibility 
make this test less favourable. The proposed cutoff for 
HPR is > 70% of the maximal ADP-induced aggregation, 
but as LTA is not standardized according to the concentra-
tion of agonist, centrifuging time and speed, this sharp 
cut point is not generalizable for different centers. LTA 
is able to predict ischemic events with a sensitivity be-
tween 60–79%, with a specificity of 59–82% and an area 
under the receiver operating curve (AUC) of 0.73–0.85, 
and an odds ratio (OR) for ischemic events in the range 
of 3–35 [52, 56, 59, 123–125]. Additionally, LTA has been 
shown to predict stent thrombosis and bleeding events 
[47, 49, 51, 52]. 
Impedance aggregometry:  
multiple electrode aggregometry
Multiple electrode aggregometry (MEA) is measuring 
whole blood platelet aggregation. ADP is used as agonist 
and, depending on the test, the antagonist PGE1 may be 
added (high sensitivity ADP test (ADP-HS)). Changes in 
the electrical impedance caused by adhesion and aggre-
gation of platelets on two independent electrode-set sur-
faces is measured and expressed as U (units) [100, 126, 
127]. The cut-off values to separate patients with HPR in 
prior studies were around 46-50 U (Table II) [100, 126, 127]. 
MEA can predict stent thrombosis quite effectively (OR: 
9–37; AUC: 0.78–0.92; sensitivity: 70–90% and specifici-
ty: 84–100%) [46, 48, 63]. Similarly to LTA, MEA has been 
shown to predict major bleedings (AUC: 0.61–0.74; sensi-
tivity: 72–77% and specificity: 62–66%) [64, 65, 128, 129]. 
VASP phosphorylation 
Measurement of VASP phosphorylation, that is a sec-
ond messenger in one of the intracellular signalling path-
ways downstream of the P2Y12 receptor, forms the basis of 
this assay (BioCytex, Marseille, France) [130, 131]. Serine 
239-phosphorylated VASP is labelled with a monoclonal 
antibody followed by a  secondary fluorescein isothio-
cyanate (FITC)-conjugated polyclonal goat-anti-mouse 
antibody and then measured using a  flow cytometer. 
Platelet reactivity is expressed as platelet reactivity 
index (PRI%). Due to this unique technique, the VASP as-
say is highly reproducible even after 24 h of sample stor-
age [90]. The VASP assay is the most specific assay for 
P2Y
12
 signalling, because it evaluates the extent of P2Y
12
 
receptor inhibition without influencing the P2Y
1
 receptor 
with agonist. The cut-off for VASP to separate patients 
with HPR is 50% (70) PRI [93]. A positive VASP test result 
corresponded to an OR = 1–23 [124, 131] to develop a stent 
thrombosis or MACE (AUC: 0.55–0.79) with high sensitivity 
(70–100%) [48, 132] but low specificity (25–37%) (Table III).
VerifyNowTM 
The VerifyNowTM assay (Accumetrics, San Diego, 
USA) measures the agonist-induced activation of plate-
lets and their binding to fibrinogen-coated polystyrene 
beads. Once the platelets have bound to the beads, the 
platelet-bead complexes fall out of the solution and in-
frared-light transmittance increases. The assay uses ADP 
as agonist and PGE1 as antagonist and results are report-
ed as P2Y
12
 reaction units (PRU) [133]. Beside the higher 
costs, the VerifyNowTM test shares the same advantag-
es as the MEA, such as whole blood test condition, fast 
preparation time and small blood volume requirement. 
Although prior studies suggested 235 PRU to separate 
patients with HPR, data from the largest meta-analysis 
[70] and a sub-analysis of the GRAVITAS study suggest 
the benefit of a  lower cutoff, 208 PRU (Table IV). Veri-
fyNowTM has been shown to predict MACE (OR = 1–6.5; 
AUC: 0.56–0.87, sensitivity: 60–80% and specificity: 
63–92%; Table IV) and major bleeding events (OR = 0.94; 
AUC = 0.84, sensitivity: 81% and specificity: 80%) [120, 
134, 135] (Table IV).
Platelet Function Analyzer (PFA-100 TM)
The PFA-100TM (Dade Behring, Marburg, Germany) 
measures the time required for occlusion of a capillary 
tube by platelet aggregates (closure time – CT) under 
high shear rates (5000–6000 s–1). To measure the effect 
of ADP antagonists, the membrane is coated with col-
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lagen/adenosine diphosphate (CADP) or collagen/ADP/
PGE1. To date, there is conflicting data concerning the 
reproducibility of the test [136–138]. The normal value for 
CADP-CT in treatment of naive patients is 65–120 s [136]. 
Only small studies revealed the usefulness of the device 
for prediction of MACE (OR = 3–33) in clopidogrel users 
[139–142], but other studies found no association with 
clinical outcomes [59]. A  closure time ≤ 72s has a sen-
sitivity of 86%, and specificity of 76% [142] to detect is-
chemic events (Table V).
Cone and Platelet Analyzer 
The Cone and Platelet Analyzer (DiaMed, Cressier, 
Switzerland) tests thrombocyte adhesion and aggre-
gation under shear stress [143]. Adherent platelets are 
stained under flow conditions, the percentage of surface 
coverage (SC) and the average size (AS) of the objects are 
determined [144]. The variability is relatively low (< 5%). 
To date, no study could show that the CPA is sensitive 
enough to predict ischemic events in clopidogrel-treated 
patients (AUC: 0.53–0.62; Table V).
Plateletworks
The Plateletworks (Helena Laboratories, Beaumont, 
Texas) is based on counting platelets before and after 
ADP agonist incubation. The ratio between the aggregat-
ed platelets after stimulation and the platelet count in 
the reference tube is used as the degree of platelet ag-
gregation [59]. One study investigated the predictive val-
ue of Plateletworks for ischemic events. In the POPULAR 
study, the Plateletworks assay predicted the composite 
of major ischemic events with a sensitivity of 63%, speci-
ficity of 59% und the AUC of 0.61 (Table V) [59].
Thrombelastography (TEG) 
The TEG haemostasis analyser (Haemoscope Corp., 
Niles, Illinois) only measures platelet-fibrin clot strength 
and is therefore insensitive to P2Y
12
 inhibition and aspirin 
effect. P2Y
12
 receptor inhibitions can be measured only in 
modified protocols (Table V) [123, 125, 127, 145]. 
Limitations of platelet function testing
It is well known that technical factors, like type of anti-
coagulant or agonist used, time delay and pipetting errors, 
can influence the results of platelet testing [146, 147]. 
Beside all technical obstacles related to the proce-
dure itself we must not forget that all these ex vivo tests 
do not reproduce the complexity of thrombocyte activa-
tion in vivo. Moreover, those tests ignore other platelet 
activating factors during ACS that might influence out-
come, such as cytokines or other paracrine factors [148]. 
Because of this fact, one cannot assume that an in vitro 
observed clopidogrel effect will show the same efficacy 
in vivo, but vice versa one can prove at least the pharma-
cological efficacy, because if a drug fails to block ADP-in-
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duced aggregation in vitro, it will also fail in vivo. For that 
reason, platelet function assays cannot overcome the 
uncertainty of antithrombotic therapy efficacy in all pa-
tients.
It should be emphasized that the consensus regard-
ing the optimal cut-off for HPR is necessary as well as 
standardization of methods before platelet function test-
ing is introduced in clinical practice. 
Genes associated with the response 
variability to clopidogrel
Cytochrome P450 genetic polymorphisms
Due to its complex metabolism, P2Y
12
 inhibitors in-
volve multiple genes in absorption, activation, and inhi-
bition of the receptor. Those detected gene variants have 
been shown to be associated with both bleeding and is-
chemic events. 
Although CYP2C9 has an integral role in clopidogrel 
metabolism, the sparse data do not support the genotyp-
ing for CYP2C9*3 for prediction of events [87, 149].
CYP2C19*2 (loss of function allele), the most common 
known allele with 30% of Caucasians and up to 50% 
Asian being carriers, is associated with a  reduced anti-
platelet effect of clopidogrel and increased risk for ad-
verse cardiovascular events [87, 150–154]. Although the 
CYP2C19*2 allele accounts only for 5–12% of the varia-
tion in the response to clopidogrel, several studies have 
shown an influence of CYP2C19*2 on clinical outcome 
[91, 95, 154–156]. Platelet function studies have shown 
a  gene-dose effect in carriers of this polymorphism, 
showing that increase of dosage led to a sufficient level 
of platelet inhibition in heterozygous patients, whereas 
most homozygous patients failed to respond despite dai-
ly doses of 300 mg clopidogrel (Table VI) [157]. 
Due to a relatively low allele frequency (< 1%), other 
identified CYP2C19 variants (*3–*8) have only a minor im-
pact on HPR [149, 158, 159].
In contrast to CYP2C19*2, CYP2C19*17 is a  gain of 
function mutation leading to intensified activation of 
clopidogrel and so-called ultra-metabolizers with exag-
gerated bioactivation of clopidogrel. Data on whether 
there is an association of CYP2C19*17 with haemorrhagic 
events is conflicting, and to date not convincing [120, 155, 
156, 160, 161].
ABCB1
Thienopyridine absorption is mediated via the intes-
tinal efflux transport pump P-glycoprotein encoded by 
the ABCB1 gene (MDR1). The influence of different ABCB1 
alleles is unclear. Some studies have shown that patients 
harbouring genetic variants in ABCB1 (specifically ho-
mozygous for the C3435T variant), have lower levels of 
the active compound and higher rates of adverse clinical 
outcomes (Table VI). However, this finding could not be 
confirmed in several subsequent studies. Further studies 
are needed to clarify the impact of this gene on the anti-
platelet effect of clopidogrel [34, 162, 163]. 
PON1
PON1 QQ192, a genetic variant in the gene encoding 
for the paraoxonase 1 (PON1) enzyme was linked to lower 
clopidogrel active metabolite concentrations in one study 
[164], which however was not confirmed in the following 
studies [91, 150, 165–167] (Table VI).
ITGB3 
ITGB3 that encodes the integrin β3 of the GP IIb/IIIa 
receptor has been linked with response variability of 
clopidogrel treatment and the risk of stent thrombosis 
[87]. Again, these results are challenged by another study 
that could not confirm these observations [158].
P2Y12
Genetic variations for the gene encoding the binding 
site for clopidogrel active metabolite on the P2Y
12
 recep-
tor have shown a reduced efficacy of clopidogrel, but the 
clinical importance is doubtable [87, 158, 168].
IRS-1
Polymorphism of the insulin receptor substrate (IRS)-1 
have been shown to be associated with hyperactive 
platelets and increased risk for ischemic events in pa-
tients with type 2 DM and stable coronary artery disease 
[169].
Studies investigating personalized 
antiplatelet treatment
The last decades of clopidogrel use have raised con-
cerns that the “one dose fits all” approach is questiona-
ble in P2Y
12
-treated patients. There are numerous studies 
that linked HPR on clopidogrel to adverse ischemic events 
and gave credit to the need of platelet inhibition testing 
in case of clopidogrel. In multiple trials, it has been ob-
served that ADP-antagonist induced platelet inhibition 
can be improved with increased clopidogrel loading and 
maintenance doses or simply by switching to novel com-
pounds like prasugrel or ticagrelor. For example, increase 
to 150 mg maintenance dose of clopidogrel resulted in 
more intense inhibition of platelet aggregation than 
administration of the standard 75 mg dose in a subset 
of patients [170–172]. Nevertheless, it must be empha-
sized that increase in dosage is not sufficient in a num-
ber of patients, as it has been shown that even 900 mg 
loading doses of clopidogrel did not overcome HPR to 
clopidogrel in homozygous CYP2C19*2 allele carriers 
[157]. Adjusted loading doses of clopidogrel according to 
platelet monitoring were shown to achieve a  reduction 
of MACE without an increase of bleeding complications, 
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however this strategy is not as sufficient as switch to pra-
sugrel or ticagrelor [79, 173, 174]. Concordant with this, 
intensified platelet inhibition with GP IIb/IIIa antagonists 
could be used as a “bridging strategy” at the time point 
of PCI [175] and showed to lower the incidence of MACE 
without increased in-hospital bleeding rates in smaller 
studies [176, 177].
Most importantly, three randomized clinical trials 
(ARCTIC, n = 2,440; GRAVITAS, n = 2,200; and TRIGGER- 
PCI, n = 423) investigated if the outcome can be influ-
enced using individualized antiplatelet strategy. In the 
GRAVITAS trial, clopidogrel treated patients with HPR re-
ceived either standard dosing of clopidogrel or a second 
clopidogrel loading dose of 600 mg plus a maintenance 
dose of 150 mg. Within the 6-month follow-up, no sig-
nificant differences in event rates could be shown in this 
patient population with a  low-to-moderate thrombotic 
risk [178]. The TRIGGER-PCI trial compared prasugrel ver-
sus clopidogrel in patients with low thrombotic risk. The 
trial had to be stopped prematurely, because an interim 
analysis indicated a lower than expected incidence of the 
primary endpoint. Therefore, no meaningful conclusions 
may be drawn regarding clinical events from this study 
[179]. The ARCTIC trial included patients with low to mod-
erate thrombotic risk with planed coronary stenting, that 
were randomised to bedside platelet function monitoring 
versus no monitoring. In the monitoring arm, antiplatelet 
therapy was intensified by increasing the dose of aspirin 
or an additional loading dose followed by an increased 
maintenance dose of clopidogrel, by additional treatment 
with a GP IIb/IIIa inhibitor or by switching to prasugrel. 
Adjustment of antiplatelet therapy based on platelet func-
tion monitoring did not lead to any improvement in the 
composite endpoint of coronary ischemic events [180]. 
There are several possible explanations why these tri-
als failed to show improved clinical outcome. Firstly, the 
three trials (GRAVITAS, TRIGGER-PCI, ARCTIC) only includ-
ed low-to-moderate risk patients, whereas STEMI patients 
with a much higher ischemic risk were excluded. Moreover, 
in ARCTIC and GRAVITAS trials, only a minority of patients 
included had a non-ST-elevation-ACS (NSTE-ACS), whereas 
the TRIGGER-PCI trial included only patients with elective 
drug-eluting stent implantation during PCI and without 
procedural complications [179]. It is likely that exclusion 
of high-risk patients may have accounted in part for the 
negative study results. Based on these findings one can 
argue that intensified antiplatelet treatment might not 
be beneficial in patients with a low-to-moderate risk for 
thrombotic events, but improve outcome in higher-risk 
patients or in those with a high risk for stent thrombosis 
[181]. In line with this assumption, Aradi et al. could prove 
in a meta-regression analysis that the net clinical benefit 
of intensified P2Y
12
 inhibition depends on the baseline risk 
for stent thrombosis [182]. This meta-analysis including 
10 randomized trials with more than 4000 patients also 
proved that the intensified antiplatelet treatment was 
associated with a significant reduction in cardiovascular 
mortality, stent thrombosis and MI [182]. The net clinical 
benefit of a personalized antiplatelet treatment also has 
been shown in the MADONNA study [79, 183]. Similarly, 
individualisation of dual antiplatelet therapy minimised 
early thrombotic events in an all-comers PCI population 
without increasing bleeding in an IDEAL registry [184].
Individualised antiplatelet therapy – 
algorithm approach
Due to the lack of prospective double-blind ran-
domised studies demonstrating an improvement in clin-
ical outcome by personalised antiplatelet therapy, there 
is no recommendation regarding a  routine approach of 
individualised antiplatelet therapy. To date, there is only 
a class IIb recommendation for platelet function testing to 
facilitate the choice of P2Y
12
 inhibitor in selected patients 
on clopidogrel at high risk for thrombotic events [185].
The novel platelet inhibitors prasugrel and ticagrelor 
have been shown to be superior concerning platelet in-
hibition and reduction of thrombotic events and for that 
it is feasible to use those compounds in all ACS patients, 
especially those at high risk. Nevertheless the ACC/AHA 
guidelines recommend either clopidogrel or ticagrelor or 
prasugrel in interventionally managed ACS (all of them 
received a class IB recommendation) and because of that 
an individualized antiplatelet therapy is conceivable. For 
that purpose it might be useful to use an algorithm for 
personalised antiplatelet therapy in patients who are at 
high thrombotic risk. This global risk algorithm is based 
on clinical (PREDICT score), biological (platelet function) 
and genetic (CYP2C19*2 carrier status) information [186]. 
Nevertheless, this algorithm has not been tested pro-
spectively yet.
Conclusions
Although the tailored antiplatelet treatment moni-
tored by platelet function testing seems to be feasible, 
the contradictory results of smaller registry studies and 
larger randomized trials with regards to outcome leave 
a  big uncertainty. It is tempting to speculate that the 
different study populations, follow-ups, treatment strat-
egies, study endpoints or time-points of blood sampling 
and therapy adjustment might disguise the real effect 
of tailored treatment [181]. Therefore, further research is 
needed to define:
i)  patient populations, which would benefit from the 
tailored antiplatelet strategy in terms of net clinical 
outcome,
ii)  which time points of platelet function testing are 
most predictive for outcome,
iii) whether multiple testing is necessary,
iv) whether genotyping adds useful information,
v) how tailored antiplatelet strategy should be applied 
to patients with bleeding events,
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vi) whether algorithm based approach to tailored anti-
platelet strategy is feasible and improves net clinical 
outcome.
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